Related Experiment Video
Updated: Jun 4, 2025
10:18
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
13.7K
Lymphoma follow-up pathway: A 10-year study to guide practice
Charlotte Ryan1, Dervla Kelly2, Rajnish K Gupta3
1Cancer Services, University Hospital Limerick, Ireland.
Summary
Routine follow-up for lymphoma survivors rarely detects relapse, which is usually found via patient symptoms. Personalized care plans and direct access to services are recommended over indefinite surveillance for detecting recurrence.
Area of Science:
- Oncology
- Hematology
- Clinical Medicine
Background:
- Lymphoma survivors treated with curative intent undergo indefinite follow-up, often at physician's discretion.
- Current surveillance protocols may not be optimal for detecting relapse in Diffuse Large B-cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL) patients.
Purpose of the Study:
- To investigate the clinical, biochemical, and radiological presentation of DLBCL and HL patients at recurrence.
- To determine if relapses were detected during scheduled follow-up appointments.
Main Methods:
- Cross-sectional study of 226 DLBCL and HL patients on surveillance.
- Statistical analysis of patient characteristics at recurrence.
- Kaplan-Meier estimator used to assess time to recurrence.
Main Results:
- Only 13% of patients relapsed, with 73% occurring within 5 years.
- All relapses were detected at unscheduled appointments, primarily due to patient-reported symptoms (97%).
Conclusions:
- Routine follow-up, especially beyond 5 years, lacks evidence for detecting relapse.
- Survivorship benefits of routine visits should be considered.
- Personalized follow-up pathways with direct access and clear care plans are recommended.
